Characterization and Long-Term Prognosis of Postmyocarditic Dilated Cardiomyopathy Compared With Idiopathic Dilated Cardiomyopathy
Related Experiment Video
Updated: Mar 17, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Marco Merlo1, Marco Anzini1, Rossana Bussani2
1Cardiovascular Department, "Ospedali Riuniti" and University of Trieste, Trieste, Italy.
Insights
Postmyocarditic dilated cardiomyopathy (PM-DC) patients show a better long-term prognosis than those with idiopathic dilated cardiomyopathy (IDC). Identifying the cause of dilated cardiomyopathy (DC) is crucial for assessing patient outcomes.
Area of Science:
- Cardiology
- Pathology
Background:
- Dilated cardiomyopathy (DC) has varied causes and uncertain prognoses.
- The long-term outlook for postmyocarditic dilated cardiomyopathy (PM-DC) is not well understood.
Purpose of the Study:
- To evaluate the clinical course and long-term prognosis of patients with PM-DC.
- To compare the outcomes of PM-DC with idiopathic dilated cardiomyopathy (IDC).
Main Methods:
- Analysis of 175 DC patients with endomyocardial biopsy (EMB) data.
- PM-DC defined by EMB findings or persistent dysfunction post-myocarditis.
- Follow-up evaluations at 24, 60, and 120 months.
Main Results:
- 41% of patients (72/175) had PM-DC.
- PM-DC patients were more often female and had less family history of DC.
- PM-DC showed a trend towards slower progression and significantly lower rates of death/heart transplantation (25% vs. 48% for IDC) after 40 months.
Conclusions:
- PM-DC is associated with a better long-term prognosis compared to IDC.
- PM-DC demonstrated an independent protective role in long-term outcomes.
- Etiologic characterization is vital for prognostic assessment in DC.
Abstract:
Dilated cardiomyopathy (DC) is the final common pathway of different pathogenetic processes and presents a significant prognostic heterogeneity, possibly related to its etiologic variety. The characterization and long-term prognosis of postmyocarditic dilated cardiomyopathy (PM-DC) remain unknown. This study assesses the clinical-instrumental evolution and long-term prognosis of a large cohort of patients with PM-DC. We analyzed 175 patients affected with DC consecutively enrolled from 1993 to 2008 with endomyocardial biopsy (EMB) data available. PM-DC was defined in the presence of borderline myocarditis at EMB or persistent left ventricular dysfunction 1 year after diagnosis of active myocarditis at EMB. Other patients were defined as affected by idiopathic dilated cardiomyopathy (IDC). Analysis of follow-up evaluations was performed at 24, 60, and 120 months. We found 72 PM-DC of 175 enrolled patients (41%). Compared with IDC, patients with PM-DC were more frequently females and less frequently presented a familial history of DC. No other baseline significant differences were found. During the long-term follow-up (median 154, first to third interquartile range 78 to 220 months), patients with PM-DC showed a trend toward slower disease progression. Globally, 18 patients with PM-DC (25%) versus 49 with IDC (48%) experienced death/heart transplantation (p = 0.045). The prognostic advantage for patients with PM-DC became significant beyond 40 months of follow-up. At multivariable time-dependent Cox analysis, PM-DC was confirmed to have a global independent protective role (hazard ratio 0.53, 95% confidence interval 0.28 to 0.97, p = 0.04). In conclusion, PM-DC is characterized by better long-term prognosis compared with IDC. An exhaustive etiologic characterization appears relevant in the prognostic assessment of DC.
More Related Videos
12:24Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
14:39Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy